- $289.46bn
- $331.15bn
- $56.33bn
European shares muted as oil rally fuels caution; Novartis tumbles (updated)
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Sarepta, Dyne fall after Novartis muscle disorder trial failure
Sarepta, Dyne sink after Novartis muscle disorder trial failure
Ionis Pharma tumbles after heart drug fails late-stage trial
Amgen falls after Novartis trial setback, BMO downgrade
Amgen falls after Novartis trial setback, BMO downgrade
European shares dip on oil-led inflation woes; Novartis set for worst day on record
Live Markets: Negative drivers pile up
European shares dip as higher crude revives inflation worries; Novartis drags
Novartis twin drug trial setbacks pile pressure on pipeline, CEO (updated)
Novartis seen down after second pipeline setback in two days
Live Markets: Europe before the bell: Back to business
Novartis announces trial setback on del-desiran drug
Sandoz bets big on biosimilars, aims to double group sales by 2035 (updated)
Switzerland's Sandoz expects rapid mid-term growth
Brief: Novartis Provides Update On Delpacibart Etedesiran (Del-Desiran) Phase Iii Harbor Study
European shares subdued as surging crude sharpens focus on ECB rate path (updated)
European shares dip as higher oil prices weigh; Novartis slips